The uptick in the Morepen Labs share came after the company announced that it has rolled out ‘Empamore.’ Empamore is used to ...

Pharmaceutical company Morepen Laboratories Ltd on Monday (March 17) said it has launched a new treatment for Type 2 diabetes, heart failure, and chronic kidney disease. The drug, Empamore, is said to ...

Haryana: Morepen Labs has announced that the Ministry of Corporate Affairs has approved the incorporation of 'QUICK MED ...

Morepen Laboratories Limited announces the launch of Empamore, a game-changing treatment for Type 2 Diabetes Mellitus, Heart ...

Morepen Labs has executed a Business Transfer Agreement (BTA) with Morepen Medtech for the transfer of its medical devices ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Morepen Laboratories surged 8.90% to Rs 46.61 after the company launched Empamore, an affordable treatment for type 2 diabetes, heart failure, and chronic kidney disease in India.

Dr. Morepen is targeting Rs 100 crore in revenue over the next three years from its newly launched wellness product, ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

New Delhi [India], January 27: This Republic Day, Dr. Morepen (NSE:MOREPENLAB), a name synonymous with trust and innovation in healthcare, proudly introduces the Dr. Morepen Sync App, a thoughtful ...